v3.26.1
Interim Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]        
Net sales $ 1,591 $ 1,615 $ 2,972 $ 2,983
Cost of goods sold 1,305 1,337 2,474 2,469
Gross profit 286 278 498 514
Selling, general, and administrative expense 469 424 616 547
Research and development expense 27 28 53 55
Restructuring, asset-related, and other charges 3 18 16 51
Total other operating expenses 499 470 685 653
Equity in earnings of affiliates 9 9 17 17
Interest expense, net (68) (67) (137) (133)
Loss on extinguishment of debt (2) 0 (11) 0
Other income, net 273 2 296 6
Loss before income taxes (1) (248) (22) (249)
Provision for income taxes 273 131 281 135
Net loss (274) (379) (303) (384)
Less: Net income attributable to non-controlling interests 0 1 0 1
Net loss attributable to Chemours $ (274) $ (380) $ (303) $ (385)
Per share data        
Basic (loss) earnings per share of common stock [1] $ (1.81) $ (2.53) $ (2.01) $ (2.56)
Diluted (loss) earnings per share of common stock [1],[2] $ (1.81) $ (2.53) $ (2.01) $ (2.56)
[1] Figures may not recalculate exactly due to rounding. Basic and diluted earnings per share are calculated based on unrounded numbers.
[2] In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS, as their inclusion would have an anti-dilutive effect. As such, with respect to the measure of diluted EPS, the impact of 1,588,513 and 1,204,120 potentially dilutive securities is excluded from the calculation for three and six months ended June 30, 2026, respectively. Additionally, with respect to the measure of diluted EPS, the impact of 268,070 and 379,632 potentially dilutive securities is excluded from the calculation for the three and six months ended June 30, 2025, respectively.